Dutch-based Meatable Acquires Uncommon Bio’s Platform

This acquisition enhances Meatable’s capabilities, combining both companies’ technologies, product pipelines, and expertise to advance cultivated meat development.

Founded in 2017, Uncommon Bio initially focused on producing meat from cells before developing innovative methods to deliver RNA into cells. RNA carries instructions from DNA, guiding protein production.

Read Also - Loft Dynamics Secures $24M In Series B Round

The company later spun out a medical venture, designing treatments that target multiple cellular pathways using polysaccharide-based delivery systems. Early efforts focus on serious lung diseases, such as idiopathic pulmonary fibrosis, with backing from investors including BioNTech, Sam Altman, Balderton, Lowercarbon, and Redalpine.

Speaking on the development, Benjamina Bollag, CEO of Uncommon Bio, says, “I’m incredibly proud of what we’ve built at Uncommon Bio, a legacy of innovation and bold thinking in cultivated meat. After deciding to focus on therapeutics, we wanted to find the best home for our technology, and it’s exciting to see Meatable carry our work forward and apply it at scale.”

“I look forward to continuing our collaboration and watch their continued success and global impact in the years ahead.”

By combining Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies with its patented opti-ox system, Meatable now offers a multi-platform cultivated meat solution. This integration accelerates product development, supports compliance with regional regulations, and enables the company to meet diverse consumer preferences and cultural requirements.

Jeff Tripician, CEO of Meatable, says “This acquisition is more than a strategic step – it sets a new standard for cultivated meat production. By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale.”

“This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”

Meatable’s acquisition of Uncommon Bio brings in technology, patents, and proprietary assets, including methods for producing chicken, lamb and other breeds, plus a regulatory dossier for approvals across multiple regions. The company is also forming partnerships along the meat supply chain to scale production sustainably and reduce risks from animal-borne diseases.

Aris de Rijke, CTO at Meatable, says, “The value of the IP is strengthened by the caliber of investors who have supported Uncommon’s mission from the start. We’re proud to carry forward technology that has earned the trust of such respected backers, like Apollo Projects and Lower Carbon Capital, further fueling our path toward success at scale.”

With expanded intellectual property, cell lines, and applications, Meatable now runs a multi-platform cultivated meat strategy, aiming to produce sustainable, scalable meat for global consumption.

About Meatable

Meatable develops cultivated meat technology that complements existing meat supply chains, partnering with producers to create animal-free meat. Its innovative process is faster than conventional methods, aiming to meet rising global protein demand while providing sustainable, scalabl and scientifically advanced solutions for the future of food production.